UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/582,549	02/04/2008	Eran Pichersky	2115-002692/US/NPB	4762	
	7590 02/04/201 CKEY & PIERCE, P.L	EXAMINER			
P.O. BOX 828	,	GEBREYESUS, KAGNEW H			
BLOOMFIELD HILLS, MI 48303			ART UNIT	PAPER NUMBER	
			1656		
			MAIL DATE	DELIVERY MODE	
			02/04/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Sup	oplemental
Notice	of Allowability

Application No.	Applicant(s)	
10/582,549	PICHERSKY ET AL.	
Examiner	Art Unit	
KAGNEW H. GEBREYESUS	1656	

	KAGNEW H. GEBREYESUS	1656					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included nerewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.							
1. This communication is responsive to 8/21/2009.							
2. ☑ The allowed claim(s) is/are <u>1 and 10-16</u> .							
<ul> <li>3.</li></ul>	e been received. e been received in Application No. cuments have been received in thi of this communication to file a repl MENT of this application.  hitted. Note the attached EXAMINE es reason(s) why the oath or decla st be submitted. son's Patent Drawing Review ( PTO) s Amendment / Comment or in the .84(c)) should be written on the draw the header according to 37 CFR 1.12 stit of BIOLOGICAL MATERIAL	s national stage applically complying with the red R'S AMENDMENT or Nation is deficient. D-948) attached Office action of wings in the front (not the I(d). must be submitted.	quirements OTICE OF				
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. Notice of Informal 6. Interview Summal Paper No./Mail D 7. Examiner's Amen 8. Examiner's Stater 9. Other /Andrew Wang/ Supervisory Patent E	y (PTO-413), ate dment/Comment nent of Reasons for Allo					

## **DETAILED ACTION**

This supplemental allowance is being mailed to the applicant to rectify an inadvertent error in the previous examiner's amendment of claim 14 (see below). Any inconvenience is regretted.

Applicant's response dated August 21, 2009 in reply to the Office Action mailed on April 22, 2009 is acknowledged. Claims 2-9, 17-18 are cancelled. Claims 1, 10-16 are present for examination.

## Withdrawn - objection to Specification

All objections and rejections not reiterated in the instant action are hereby withdrawn.

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Stan Erjavac on 10/23/2009.

Amend the priority data on the first line of the specification:

Application/Control Number: 10/582,549 Page 3

Art Unit: 1656

This Application is a 371 of PCT/US04/40321 filed on 12/02/2004 and claims benefit of priority from U.S. Provisional Application No. 60/528,202, filed on December 10, 2003.

Claim 14. On line 1 of claim 14 replace the recitation "the" with "a".

**Conclusion:** Claims 1, 10-16 are allowed.

An isolated polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 comprising a geraniol synthase (GES) capable of converting a geranyl phosphate to geraniol is not anticipated by the prior art.

A shortened statutory period for reply to this action is set to expire ONE MONTH from the mailing date of this action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAGNEW H. GEBREYESUS whose telephone number is (571)272-2937. The examiner can normally be reached on 8:30am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/582,549 Page 4

Art Unit: 1656

If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kagnew H Gebreyesus/ Examiner, Art Unit 1656 10/09/2009

/Manjunath N. Rao /

Supervisory Patent Examiner, Art Unit 1656